Novel drug - dinutuximab for high-risk neuroblastoma
Neuroblastoma is the most common extracranial tumor in children aged <5 years. Prognosis of high-risk neuroblastoma is not good even after use of aggressive chemotherapy. Newer drug anti-GD2 monoclonal antibodies, dinutuximab in combination with granulocyte-macrophage colony-stimulating factor or in...
में बचाया:
| मुख्य लेखकों: | , , |
|---|---|
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
SAGE Publishing
2018-01-01
|
| श्रृंखला: | Apollo Medicine |
| विषय: | |
| ऑनलाइन पहुंच: | http://www.apollomedicine.org/article.asp?issn=0976-0016;year=2018;volume=15;issue=3;spage=132;epage=134;aulast=Kushwah |
| टैग: |
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|